Literature DB >> 10520842

Hyoscyamine as a pharmacological adjunct in colonoscopy: a randomized, double blinded, placebo-controlled trial.

N J Shaheen1, D J Robertson, M A Crosby, S J Furs, D T May, W R Harlan, I S Grimm, K L Isaacs, E M Bozymski.   

Abstract

OBJECTIVE: Investigators have assessed the utility of antispasmodic agents in colonoscopy, with conflicting results. The aim of this study is to determine the effects of premedication with hyoscyamine, an anticholinergic antispasmodic, on outcomes in colonoscopy.
METHODS: A total of 165 patients undergoing elective colonoscopy were randomized in a double blinded fashion to one of three arms: intravenous hyoscyamine (0.25 mg), oral hyoscyamine (0.25 mg), or placebo, administered 20-40 min before colonoscopy. Primary outcome measures included insertion time to cecum, patient's assessment of pain, and physician assessment of spasm. Secondary outcome measures included amount of analgesic medications used, total procedure time, amount and type of pathology visualized, and physician assessment of patient's pain.
RESULTS: Bivariate analysis showed no difference between the three groups in insertion time (13.8 min, 14.8 min, and 13.8 min for placebo, intravenous hyoscyamine, and oral hyocyamine, respectively), analgesic medication necessary, or any other primary or secondary outcome variable. Multivariate analysis controlling for potential confounders also failed to demonstrate any differences between the groups. Women had higher procedure duration and analgesic requirement, and reported more pain than did men.
CONCLUSIONS: This randomized, double blinded, placebo-controlled trial did not demonstrate efficacy of either intravenous or oral hyoscyamine as a premedication for colonoscopy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520842     DOI: 10.1111/j.1572-0241.1999.01435.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

Review 1.  Antispasmodic drugs in colonoscopy: a review of their pharmacology, safety and efficacy in improving polyp detection and related outcomes.

Authors:  Santosh Sanagapalli; Kriti Agnihotri; Rupert Leong; Crispin John Corte
Journal:  Therap Adv Gastroenterol       Date:  2016-10-03       Impact factor: 4.409

2.  Role of intravenously administered hyoscine butyl bromide in retrograde terminal ileoscopy: a randomized, double-blinded, placebo-controlled trial.

Authors:  S P Misra; M Dwivedi
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

3.  Mechanisms of hyoscine butylbromide to improve adenoma detection: A case-control study of surface visualization at simulated colonoscope withdrawal.

Authors:  James E East; Brian P Saunders; David Burling; Emily Tam; Darren Boone; Steve Halligan; Stuart A Taylor
Journal:  Endosc Int Open       Date:  2015-09-15

4.  Standards of diagnostic colonoscopy for early-stage neoplasia: Recommendations by an Asian private group.

Authors:  Yasushi Sano; Han-Mo Chiu; Xiao-Bo Li; Supakij Khomvilai; Pises Pisespongsa; Jonard Tan Co; Takuji Kawamura; Nozomu Kobayashi; Shinji Tanaka; David G Hewett; Yoji Takeuchi; Kenichiro Imai; Takahiro Utsumi; Akira Teramoto; Daizen Hirata; Mineo Iwatate; Rajvinder Singh; Siew C Ng; Shiaw-Hooi Ho; Philip Chiu; Hisao Tajiri
Journal:  Dig Endosc       Date:  2019-03-29       Impact factor: 7.559

5.  Hyoscine-N-butyl-bromide-induced hypotension and myocardial ischemia.

Authors:  Guan-Liang Chen; Wen-Hsiu Hsu
Journal:  Case Rep Crit Care       Date:  2013-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.